An open label, randomized, balanced, two treatment, two sequence, two period, truncated, two way cross-over, single-dose, oral bioequivalence study of FDC of Linagliptin 05 mg, Dapagliflozin 10 mg and Metformin Hydrochloride 1000 mg extended release Tablets (T) Manufactured by Optimus Pharma Pvt. Ltd., India with Trajenta® 5 mg (Linagliptin 05 mg) Tablet (R1) Manufactured by West-Ward Columbus Inc., USA and Marketed by Boehringer Ingelheim India Pvt. Ltd., Maharashtra, India and Xigduo® XR (Dapagliflozin and Metformin HCl Extended Release Tablets 10 mg + 1000 mg) (R2) Manufactured by AstraZeneca Pharmaceuticals LP, USA and Imported & Marketed by AstraZeneca Pharma India Ltd., Bangalore, India in normal healthy, adult human subjects under fasting condition.
An Open Label, Randomized, Balanced, Two-Treatment, Two-Sequence, Two-Period, Crossover, Single-Dose, oral bioequivalence study of Brivaracetam Sustained Release Tablets 200 mg (T) Manufactured by Optimus Pharma Pvt. Ltd., India with BRITZILAM SR (Brivaracetam Sustained Release Tablets 200 mg) (R) Manufactured by Ravenbhel Healthcare Pvt. Ltd., India and Marketed by Torrent Pharmaceuticals Ltd., India in healthy, adult, human subjects under fasting conditions.
A randomized, open label, balanced, two treatment, two period, two sequence, two way crossover, single oral dose, bioequivalence study of Tofacitinib 11mg XR extended-release tablets of Optimus Pharma Pvt. Ltd, India with XELJANZ® XR (Tofacitinib) 11 mg extended-release tablets marketed by Pfizer Labs Division of Pfizer Inc. NY. NY10017 in healthy adult human subjects under fasting conditions.
100 项与 Optimus Pharma Pvt Ltd. 相关的临床结果
0 项与 Optimus Pharma Pvt Ltd. 相关的专利(医药)
100 项与 Optimus Pharma Pvt Ltd. 相关的药物交易
100 项与 Optimus Pharma Pvt Ltd. 相关的转化医学